Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center

McElwain, 1983, High-dose intravenous melphalan for plasma-cell leukaemia and myeloma, Lancet, 2, 822, 10.1016/S0140-6736(83)90739-0 Barlogie, 1986, High-dose melphalan with autologous bone marrow transplantation for multiple myeloma, Blood, 67, 1298, 10.1182/blood.V67.5.1298.1298 Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, Intergroupe Francais du Myelome. N. Engl. J. Med., 335, 91, 10.1056/NEJM199607113350204 Child, 2003, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N. Engl. J. Med., 348, 1875, 10.1056/NEJMoa022340 Bashir, 2012, Feasibility of autologous hematopoietic stem cell transplant in patients aged >/=70 years with multiple myeloma, Leuk Lymphoma, 53, 118, 10.3109/10428194.2011.606942 Kumar, 2008, Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis, Am. J. Hematol., 83, 614, 10.1002/ajh.21191 Shah, 2015, Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the surveillance, epidemiology, and end results-medicare database, Biol. Blood Marrow Transplant., 21, 1823, 10.1016/j.bbmt.2015.05.013 Winn, 2015, The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv139 Bhatt, 2015, Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades, Clin. Lymphoma Myeloma Leuk, 15, 10.1016/j.clml.2015.02.024 Martino, 2014, Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs, Clin Lymphoma Myeloma Leuk, 14, 148, 10.1016/j.clml.2013.11.009 Costa, 2013, Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma, Biol. Blood Marrow Transplant., 19, 1615, 10.1016/j.bbmt.2013.08.002 Kumar, 2014, Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients, Leukemia, 28, 1122, 10.1038/leu.2013.313 Durie, 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Harousseau, 2010, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial, J. Clin. Oncol., 28, 4621, 10.1200/JCO.2009.27.9158 Rosinol, 2012, Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study, Blood, 120, 1589, 10.1182/blood-2012-02-408922 Moreau, 2002, Blood, 99, 731, 10.1182/blood.V99.3.731 Auner, 2015, Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years, Bone Marrow Transplant., 50, 209, 10.1038/bmt.2014.255 O'Shea, 2006, Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients, Bone Marrow Transplant., 37, 731, 10.1038/sj.bmt.1705307 Barlogie, 2008, Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989, Blood, 111, 94, 10.1182/blood-2007-06-097444 Govindarajan, 1996, Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma, Br. J. Haematol., 95, 349, 10.1046/j.1365-2141.1996.d01-1891.x